Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · see citing works

Trastuzumab emtansine for HER2-positive advanced breast cancer

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · see citing works

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Slamon, D. J., EIERMANN, W., Robert, N. J., Pieńkowski, T., Martín, M., Press, M. F., Mackey, J. R., Glaspy, J. A., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,779 · see citing works

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164 · see citing works

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900 · see citing works

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827 · see citing works

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655 · see citing works

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

† (2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,523 · see citing works

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

Burstein, M. D., Tsimelzon, A. I., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,404 · see citing works

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,252 · see citing works

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Robert, N. J., Dieras, V. C., Glaspy, J. A., Brufsky, A., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,063 · see citing works

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

Perez, E. A., Romond, E. H., Suman, V. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5730 · Cited by 981 · see citing works

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J. D., Goel, N. J., Aronson, A. B., Li, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 869 · see citing works

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

Herrera-Abreu, M. T., Palafox, M., Asghar, U. S., Rivas, M. A., Cutts, R. J., García-Murillas, I., Pearson, A., Guzmán, M., Rodríguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 768 · see citing works

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Gucalp, A., Tolaney, S. M., Isakoff, S. J., Ingle, J. N., Liu, M., Carey, L., Blackwell, K., Rugo, H. S., Nabell, L. M., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 750 · see citing works

Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722 · see citing works

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636 · see citing works

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

Schiavon, G., Hrebien, S., García-Murillas, I., Cutts, R. J., Pearson, A., Tarazona, N., Fenwick, K., Kozarewa, I., López‐Knowles, E., Ribas, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7551 · Cited by 589 · see citing works

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Chan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gökmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 562 · see citing works

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Yardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., Baselga, J. M., Gnant, M., Hortobágyi, G. N., Campone, M., Pistilli, B., Piccart, M. J., et al. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0060-1 · Cited by 522 · see citing works

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499 · see citing works

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Goldhirsch, A., Gelber, R. D., Piccart, M. J., de Azambuja, E., Procter, M. J., Suter, T. M., Jackisch, C., Cameron, D., Weber, H., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497 · see citing works

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

André, F., O'Regan, R. M., Özgüroğlu, M., Toi, M., Xu, B., Jérusalem, G., Masuda, N., Wilks, S. T., Arena, F. P., Isaacs, C. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493 · see citing works

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Brufsky, A., Hurvitz, S. A., Perez, E. A., Swamy, R., Valero, V., O’Neill, V., & Rugo, H. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1255 · Cited by 419 · see citing works

Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer

Baselga, J. M., Albanell, J., Ruı́z, A., Lluch, A. M., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.326 · Cited by 410 · see citing works

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

Baselga, J. M., Gómez, P., Greil, R., Braga, S. A., Climent, M. Á., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363 · see citing works

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Gonzalez-Angulo, A. M., Krop, I. E., Levinson, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0948 · Cited by 344 · see citing works

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Hurvitz, S. A., André, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306 · see citing works

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M. N., Johnston, S. R. D., Morales, S. M., Yardley, D. A., Melichar, B., Forero, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295 · see citing works

An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.

Zhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 286 · see citing works

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutiérrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274 · see citing works

Targeting HER2 for the Treatment of Breast Cancer

Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268 · see citing works

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Bergh, J. C. S., Bondarenko, I. M., Lichinitser, M., Liljegren, A., Greil, R., Voytko, N. L., Makhson, A. N., Cortés, J., Lortholary, A. H., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7376 · Cited by 264 · see citing works

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Dave, B., Migliaccio, I., Gutierrez, M. C., Wu, M.-F., Chamness, G. C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S. G., Huang, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7814 · Cited by 252 · see citing works

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

Majewski, I. J., Nuciforo, P. G., Mittempergher, L., Bosma, A. J., Eidtmann, H., Holmes, E. M., Sotiriou, C. P., Fumagalli, D., Jimenez, J., Aura, C. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2158 · Cited by 237 · see citing works

Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

Traina, T. A., Miller, K. D., Yardley, D. A., O’Shaughnessy, J., Cortés, J., Awada, A. H., Kelly, C. M., Trudeau, M., Schmid, P., Gianni, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1003 · Cited by 164 · see citing works

Breast Cancer, Version 1.2016

Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0176 · Cited by 160 · see citing works

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

Crown, J. P., Dieras, V. C., Starosławska, E., Yardley, D. A., Bachelot, T., Davidson, N. G. P., Wildiers, H. P. M. W., Fasching, P. A., Capitain, O., Ramos, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3391 · Cited by 151 · see citing works

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

Harbeck, N., Huang, C., Hurvitz, S. A., Yeh, D., Shao, Z., Im, S., Jung, K. H., Shen, K., Ro, J., Jassem, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00540-9 · Cited by 143 · see citing works

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

Mackey, J. R., Ramos-Vázquez, M., Lipatov, O. N., McCarthy, N. J., Krasnozhon, D., Семиглазов, В. Ф., Manikhas, A., Gelmon, K. A., Konecny, G. E., Webster, M. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1513 · Cited by 136 · see citing works

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Dickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J. A., Yeh, B. M., Lake, D. E., Dang, C. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0141 · Cited by 122 · see citing works

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy

Giuliano, M., Hu, H., Wang, Y.-C., Fu, X., Nardone, A., Herrera, S., Mao, S., Contreras, A., Gutiérrez, C., Wang, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2728 · Cited by 118 · see citing works

Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial

Pogue–Geile, K. L., Song, N., Jeong, J., Gavin, P. G., Kim, S.-R., Blackmon, N. L., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2439 · Cited by 111 · see citing works

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Perez, E. A., Dueck, A. C., McCullough, A. E., Chen, B., Geiger, X. J., Jenkins, R. B., Lingle, W. L., Davidson, N. E., Martino, S., Kaufman, P. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2642 · Cited by 106 · see citing works

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

Nahta, R., & O'Regan, R. M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2067-8 · Cited by 97 · see citing works

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

Johnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92 · see citing works

Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight

Fuqua, S. A. W., Gu, G., & Rechoum, Y. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2847-4 · Cited by 82 · see citing works

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Ma, C. X., Sanchez, C. G., Gao, F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2160 · Cited by 77 · see citing works

The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis

Wang, Y., Liu, Y., Du, Y., Yin, W., & Lu, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.794775 · Cited by 53 · see citing works

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

Baselga, J. M., Costa, F. P., Gómez, H., Hudis, C. A., Rapoport, B. L., Roche, H. H., Schwartzberg, L. S., Petrenciuc, O., Shan, M., & Gradishar, W. J. (2013) · Trials · doi:10.1186/1745-6215-14-228 · Cited by 37 · see citing works

Targeting thyroid hormone receptor beta in triple-negative breast cancer

Gu, G., Gelsomino, L., Covington, K. R., Beyer, A. R., Wang, J. C. K., Rechoum, Y., Huffman, K. E., Carstens, R. M., Andò, S., & Fuqua, S. A. W. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3354-y · Cited by 35 · see citing works

ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action

Gu, G., & Fuqua, S. A. W. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2549 · Cited by 21 · see citing works

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs

Fadoukhair, Z., Zardavas, D., Chad, M. A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.249 · Cited by 14 · see citing works

PI3K Inhibitor Improves PFS in BELLE-2 Trial

(2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2015-176 · Cited by 14 · see citing works

ESR1 Mutations Prevalent in Some Breast Cancers

(2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2015-175 · Cited by 2 · see citing works

Ebp50: A Novel Biomarker for Resistance to Endocrine and HER‐2 Targeted Therapies in Breast Cancer

gu, G., Covington, K. R., Fernandez, N., et al. (2012) · The FASEB Journal · doi:10.1096/fasebj.26.1_supplement.lb522 · Cited by 1 · see citing works

High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression

Sgarra, R., Pegoraro, S., Ros, G., Penzo, C., Chiefari, E., Foti, D., Brunetti, A., & Manfioletti, G. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.03.001 · Cited by 77 · see citing works

Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer

Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44 · see citing works

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases

(2021) · doi:10.1159/000513002 · Cited by 9 · see citing works

A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action

Zhang, X., Chen, J., Weng, Z., Li, Q., Zhao, L., Yu, N., Deng, L., Xu, W., Yang, Y., Zhu, Z., et al. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.01.009 · Cited by 49 · see citing works

Abstract 3477: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers

(2010) · doi:10.1158/1538-7445.am10-3477 · Cited by 3 · see citing works

Pertuzumab (Perjeta®)

Garca‐Saénz, J. A., Antón, F. M., & Bueno, C. (2014) · doi:10.1002/9783527682423.ch67

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer

Gleeson, J. P., Keegan, N. M., & Morris, P. G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1410132 · Cited by 19 · see citing works